German contrast media firm Schering has completed the divestiture of the radiopharmaceutical business of CIS bio international to a consortium formed by Belgian companies Ion Beam Applications and the Institut National des Radioéléments (IRE).
The sale of Schering's current radiopharmaceutical business will allow the firm to focus on MRI, CT, and optical contrast media, as well as molecular imaging agents, according to the Berlin-based firm.
By AuntMinnie.com staff writers
May 8, 2006
Related Reading
Schering board endorses Bayer offer, April 19, 2006
Schering supports Bayer offer, Merck withdraws, March 24, 2006
Schering, IBA ink radiopharma deal, February 23, 2006
Schering options joint Epix-Schering agent, February 13, 2006
Schering may sell CIS bio radiopharma unit, December 5, 2005
Copyright © 2006 AuntMinnie.com